Floatz logo

ave1625

Schizophrenia

SanofiPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

145 Active assets in the Schizophrenia cohort.

Asset / SponsorPhaseRating
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
TROSPIUM
European Group for Research In Schizophrenia
Phase 4BBB
Opc-34712
Humanis Saglık Anonim Sirketi
Phase 4BBB

View all 50 →

Same molecule, other indications

ave1625 is also rated in:

inherited lipid metabolism disorderDormant
B
Indicative ·
57 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
48 / 100
View asset →
Alzheimer diseaseDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →